Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 492-499

  Woodward, Tatia Chay ^a   Brown, Ruth ^a   Sacco, Patricia ^b   Zhang, Jie ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Budget impact; Costs; Cystic fibrosis; Tobramycin inhalation solution

Indexed keywords

TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BUDGET; COMPUTER PROGRAM; CYSTIC FIBROSIS; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MANAGED CARE ORGANIZATION; MEDICAL CARE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; UNITED STATES;

ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MODELS, ECONOMIC; PATIENT ADMISSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; UNITED STATES;

EID: 77956653863     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.505863     Document Type: Article

References (34)

1. Cystic Fibrosis Foundation. About Cystic Fibrosis -What You Need to Know, 2008. http://www.cff.org/AboutCF/
2. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62:360-367
3. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121:64-72
4. Liou TG, Adler FR, Fitzsimmons SC, et al.Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352
5. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188
6. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation: Patient Registry Annual Data Report 2006. Bethesda, MD
7. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbi-ologic markers in induced sputum after intravenous antibiotics in cystic fibro-sis. Am J Respir Crit Care Med 2003;168:1471-1475
8. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921
9. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400-406
10. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72
11. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-996
12. Flume PA, O'Sullivan BP, Robinson KA, et al.Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-969
13. Mauskopf J, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices -budget impact analysis. Value Health 2007;10:336-347
14. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30
15. Population Division US Census Bureau. Monthly estimates of the population by sex, race, and Hispanic origin for the United States: July 1, 2006. Available at: http://www.census.gov/popest/national/asrh/2007-nat-res.html
16. Razvi S, Quittell L, Sewall A, et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009;136: 1554-1560
17. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67:351-368
18. Thomson PDR. Red Book for Windows. Greenwood Village, CO: Thomson, 2008
19. Novartis. TOBI: Tobramycin Inhalation Solution, USP. Prescribing information, 2007
20. Center for Medicare & Medicaid Services. HCPCS Alpha-Numeric Index, 2008. Available at: http://www.cms.hhs.gov/HCPCSReleaseCodeSets/Downloads/ INDEX2008.pdf
21. DeVilbiss Healthcare. Products: pulmonary drug delivery, 2008. Available at: http://www.devilbisshealthcare.com
22. PARI Respiratory Equipment Inc. Products: the lower airway, the upper airway, 2008. Available at: http://www.pari.com/home/pari-products.htm
23. American Pharmaceutical Partners Inc. Tobramycin. Prescribing information
24. American Society of Health-System Pharmacists. Ceftazidime (Systemic), 2008. Available at: http://www.ashp.org/s-ashp/docs/files/practice-and-policy/ ceftazidime.pdf
25. Tice AD, Hoaglund PA, Nolet B, et al. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22:63-70S
26. MAG Mutual. Physician's Fee and Coding Guide 2008, 19th edn. Atlanta, GA: MAG Mutual Healthcare Solutions, Inc., 2007
27. Bloom MA, Barghout V, Kahler KH, et al. Budget impact of tegaserod on a managed care organization formulary. Am J Manag Care 2005;11: S27-34
28. Cooke CE, Wong W, LeeH. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. J Manag Care Pharm 2005;11:674-680
29. Velasco MV ZI, Gonzalez A, et al. Inhaled antibiotics treatment adherence in cystic fibrosis. Paper presented at: American Thoracic Society International Conference, 2002
30. Weiner JR, Toy EL, Sacco P, et al. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother 2008;9:751-766
31. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006;5: 177-185
32. Briesacher BA, Saiman L, Fouayzi H, et al. Adherence to tobramycin inhaled solution and health care utilization. Am J Respir Crit Care Med 2009; 179:A1183
33. O'Sullivan A, Sullivan JK, Higuchi K. Medication compliance and impact on health-care resource utilization and mortality among cystic fibrosis patients with P. aeruginosa. Pediatr Pulmonol 2008;S31:473-484
34. Centers for Medicare & Medicaid Services. HCPCS Alpha-Numeric Index, 2008. Available at: http://www.cms.hhs.gov/HCPCSReleaseCodeSets/Downloads/ INDEX2008.pdf